Tumor-induced osteomalacia: a clinical case report

Grebennikova, T. A.; Алексеевна, Гребенникова Татьяна; Umiarova, Diliara Sh.; Шамилевна, Умярова Диляра; Slashchuk, Konstantin Y.; Юрьевич, Слащук Константин; Degtyarev, M. V.; Владимирович, Дегтярев Михаил; Родионова, С. С.; Семеновна, Родионова Светлана; Rumyantsev, P O; Олегович, Румянцев Павел; Belaya, Zhanna; Евгеньевна, Белая Жанна

doi:10.14341/osteo10264

Cited by 6 publications

(2 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Активная диагностика началась с 2008 г., что связано с прогрессом инструментальных методов. В мире известно около 1725 клинических случаев [13,14]. Распространенность и эпидемиология из-за редкости изучены недостаточно и неизвестны.…”

unclassified

FGF23 tumor induced osteomalacia

Gronskaia

Belaya

Мельниченко

2022

Probl Endokrinol (Mosk)

Self Cite

View full text Add to dashboard Cite

Tumor induced osteomalacia is a rare acquired disease. The cause is a mesenchymal tumor secreting fibroblast growth factor 23 (FGF23). An excessive amount of FGF 23 disrupts the metabolism of phosphorus and vitamin D, which leads to severe paraneoplastic syndrome, manifested in the form of multiple fractures, severe pain in the bones and generalized myopathy. With oncogenic osteomalacia, a complete cure is possible with radical resection of the tumor. Unfortunately, localization, small size of formations and rare frequency of occurrence lead to the fact that the disease remains unrecognized for a long time and leads to severe, disabling consequences. A step-by-step approach to diagnosis improves treatment outcomes. First, a thorough anamnesis is collected, then functional visualization is performed and the diagnosis is confirmed by anatomical visualization of the tumor. After that, the method of choice is a surgical treatment. If resection is not possible, then conservative therapy with active metabolites of vitamin D and phosphorus salts is indicated. New therapeutic approaches, such as the antibody to FGF23 or the pan-inhibitor of receptors to FGF, are actively developing. This article provides an overview of modern approaches to the diagnosis and treatment of this disease.

show abstract

unclassified

FGF23 tumor induced osteomalacia

Gronskaia

Belaya

Мельниченко

2022

Probl Endokrinol (Mosk)

Self Cite

View full text Add to dashboard Cite

show abstract

“…Folpe описано всего около 450 случаев, но истинная встречаемость остается неизвестной [1]. В Российской Федерации описания ФМО единичны [16][17][18][19]. Чаще всего ФМО обнаруживаются у пациентов среднего возраста [4,20], при этом самый ранний дебют заболевания описан у девятимесячного ребенка [21], гендерные различия не выявлены (М:Ж = 1,25:1 [22]).…”

unclassified

The case of oncogenic hypophosphatemic osteomalacia

Eremkina¹,

Mirnaya²,

Горбачева³

et al. 2020

Obes. metabol.

View full text Add to dashboard Cite

Osteomalacia is a systemic bone disease, characterized by an excessive accumulation of non-mineralized osteoid and an imbalance in the organic matrix formation and mineralization. A rare cause of disease is tumor-induced osteomalacia, most often due to phosphaturic mesenchymal tumors (PMT). Usually there are benign small tumors, affecting the soft tissues and bones of any location. The basic pathogenesis of underlying oncogenic osteomalacia is a decreased renal tubular reabsorption of phosphate consequent to hyperproduction of fibroblast growth factor 23 in PMT. Clinical features are nonspecific, the average period from the symptoms onset to diagnosis reaches 3 years and at least 5 years before surgical treatment. Finding the tumour is crucial, as complete removal is curative. We present a clinical case of tumor-induced osteomalacia due to PMT required the complex differential diagnosis with other rare diseases.

show abstract

A clinical case of phosphopenic osteomalacia due to paraneoplastic secretion of metastatic prostate cance

et al. 2023

Self Cite

View full text Add to dashboard Cite

Phosphaturic mesenchymal tumor can cause osteomalacia due to excessive secretion of fibroblast growth factor 23 (FGF23), which disrupts the metabolism of phosphate and vitamin D. These tumors are predominantly benign, but less than 5% of them are malignant forms. This article presents the first clinical case in the Russian Federation of a 69-year-old patient with severe hypophosphatemia due to metastatic prostate cancer. Increased secretion of FGF23 are described in the androgen-resistent prostate cancer, which led to pronounced disorders of mineral metabolism, accompanied by a clinical symptom of weakness, pain in the bones, immobilization of the patient. The condition was regarded as worsening against the background of the progression of the disease. However, symptomatic therapy aimed at increasing the level of phosphate significantly improved the patient’s general condition. The medical community should be aware of the possibility of developing hypophosphatemia in patients with weakness and bone pain, which are not always associated with the progression of metastatic prostate cancer.

show abstract

Tumor-induced osteomalacia: a clinical case report

Cited by 6 publications

References 9 publications

FGF23 tumor induced osteomalacia

FGF23 tumor induced osteomalacia

The case of oncogenic hypophosphatemic osteomalacia

A clinical case of phosphopenic osteomalacia due to paraneoplastic secretion of metastatic prostate cance

Contact Info

Product

Resources

About